Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

FDA's Opioid REMS Review Puts Brakes On Mandatory Education Push

This article was originally published in The Pink Sheet Daily

Executive Summary

Requiring training and certification for extended-release opioids would involve at least 320,000 prescribers and impact 21 million outpatient prescriptions, reviewers note in a briefing memo that is more skeptical of the mandatory approach than FDA's leadership has been.


Related Content

Opioids May All Require Mandatory Education As US FDA Expands REMS To Immediate-Release Formulations
Restrictive REMS Is Least Favored Path For Opioid Prescriber Education
Opioid REMS Prescriber Education Should Be Mandatory, FDA Panel Says
Opioid Continuing Education Rules Hamper REMS Assessments
Opioid Product Sponsors Eye REMS Fixes To Boost Prescriber Education Uptake
Opioid REMS: FDA Sees No Clear Verdict On Risk Management Program's Impact
Califf Nomination Suffers 'Pile On': What Can FDA Do To Break Logjam?
Opioid REMS Needs Legislation Mandating Physician Training For Full Implementation
FDA Opioid REMS Proposal Leaves Advisory Panel Wanting More - i.e. Mandatory Training